针对复发或难治性急性髓性白血病的定时序贯挽救性化疗。

Clinical Hematology International Pub Date : 2020-03-01 Epub Date: 2019-12-09 DOI:10.2991/chi.d.191128.001
Bogdan Popescu, Sheenu Sheela, Julie Thompson, Sophia Grasmeder, Therese Intrater, Christin B DeStefano, Christopher S Hourigan, Catherine Lai
{"title":"针对复发或难治性急性髓性白血病的定时序贯挽救性化疗。","authors":"Bogdan Popescu, Sheenu Sheela, Julie Thompson, Sophia Grasmeder, Therese Intrater, Christin B DeStefano, Christopher S Hourigan, Catherine Lai","doi":"10.2991/chi.d.191128.001","DOIUrl":null,"url":null,"abstract":"<p><p>Therapy for those with relapsed or refractory acute myeloid leukemia is suboptimal. Studies have suggested that timed sequential salvage combination cytotoxic chemotherapy may have particular utility for that indication. We report here a series of ten such adult patients treated sequentially at a single center with EMA (cytarabine 500 mg/m<sup>2</sup>/day as continuous infusion on days 1-3 and days 8-10, mitoxantrone 12 mg/m<sup>2</sup>/day on days 1-3, and etoposide 200 mg/m<sup>2</sup>/day as continuous infusion on days 8-10). The overall complete remission rate was 40% (including 3 of 4 of those with relapsed disease) but use of this regimen was associated with prolonged cytopenia and a high rate of infectious adverse events. Even with the availability of modern infectious prophylaxis and therapies, the EMA regimen is likely best reserved for those with relapsed disease treated with curative intent prior to an allogeneic hematopoietic cell transplant.</p>","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"2 1","pages":"27-31"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e4/8a/CHI-2-1-27.PMC7079712.pdf","citationCount":"0","resultStr":"{\"title\":\"Timed sequential salvage chemotherapy for relapsed or refractory acute myeloid leukemia.\",\"authors\":\"Bogdan Popescu, Sheenu Sheela, Julie Thompson, Sophia Grasmeder, Therese Intrater, Christin B DeStefano, Christopher S Hourigan, Catherine Lai\",\"doi\":\"10.2991/chi.d.191128.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Therapy for those with relapsed or refractory acute myeloid leukemia is suboptimal. Studies have suggested that timed sequential salvage combination cytotoxic chemotherapy may have particular utility for that indication. We report here a series of ten such adult patients treated sequentially at a single center with EMA (cytarabine 500 mg/m<sup>2</sup>/day as continuous infusion on days 1-3 and days 8-10, mitoxantrone 12 mg/m<sup>2</sup>/day on days 1-3, and etoposide 200 mg/m<sup>2</sup>/day as continuous infusion on days 8-10). The overall complete remission rate was 40% (including 3 of 4 of those with relapsed disease) but use of this regimen was associated with prolonged cytopenia and a high rate of infectious adverse events. Even with the availability of modern infectious prophylaxis and therapies, the EMA regimen is likely best reserved for those with relapsed disease treated with curative intent prior to an allogeneic hematopoietic cell transplant.</p>\",\"PeriodicalId\":10368,\"journal\":{\"name\":\"Clinical Hematology International\",\"volume\":\"2 1\",\"pages\":\"27-31\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e4/8a/CHI-2-1-27.PMC7079712.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Hematology International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2991/chi.d.191128.001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/12/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Hematology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2991/chi.d.191128.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/12/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

对复发或难治性急性髓性白血病患者的治疗效果并不理想。研究表明,定时序贯挽救性联合细胞毒性化疗在该适应症中可能具有特殊疗效。我们在此报告了在一个中心使用 EMA(阿糖胞苷 500 毫克/平方米/天,第 1-3 天和第 8-10 天连续输注;米托蒽醌 12 毫克/平方米/天,第 1-3 天连续输注;依托泊苷 200 毫克/平方米/天,第 8-10 天连续输注)连续治疗的 10 例此类成人患者。总的完全缓解率为 40%(包括 4 例复发患者中的 3 例),但使用该方案会导致细胞减少时间延长,感染性不良反应发生率高。即使现在有了现代的感染预防和治疗方法,EMA 方案也可能只适用于那些在异基因造血细胞移植前接受治愈性治疗的复发患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Timed sequential salvage chemotherapy for relapsed or refractory acute myeloid leukemia.

Timed sequential salvage chemotherapy for relapsed or refractory acute myeloid leukemia.

Timed sequential salvage chemotherapy for relapsed or refractory acute myeloid leukemia.

Therapy for those with relapsed or refractory acute myeloid leukemia is suboptimal. Studies have suggested that timed sequential salvage combination cytotoxic chemotherapy may have particular utility for that indication. We report here a series of ten such adult patients treated sequentially at a single center with EMA (cytarabine 500 mg/m2/day as continuous infusion on days 1-3 and days 8-10, mitoxantrone 12 mg/m2/day on days 1-3, and etoposide 200 mg/m2/day as continuous infusion on days 8-10). The overall complete remission rate was 40% (including 3 of 4 of those with relapsed disease) but use of this regimen was associated with prolonged cytopenia and a high rate of infectious adverse events. Even with the availability of modern infectious prophylaxis and therapies, the EMA regimen is likely best reserved for those with relapsed disease treated with curative intent prior to an allogeneic hematopoietic cell transplant.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信